HDL level or HDL function as the primary target in preventive cardiology;HDL-Spiegel oder HDL-Funktion als primäres Target der präventiven Kardiologie

Herz

Volumn 37, Issue 1, 2012, Pages 51-55

  Schaefer, J R ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Atherosclerosis; CAD prevention; CETP inhibitors; HDL cholesterol

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; HEART INFARCTION; HUMAN; LIPID METABOLISM; PRIMARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; NIACIN; PYRIMIDINES; PYRROLES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; SCAVENGER RECEPTORS, CLASS B; SULFONAMIDES; SURVIVAL RATE; UP-REGULATION;

EID: 84857633999     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-011-3563-z     Document Type: Article

References (22)

1. http://www.destatis.de/jetspeed/portal/cms/
2. Ford ES, Ajani UA, Croft JB, et al. (2007) Explaining the decrease in US deaths from coronary disease 1980-2000. N Engl J Med 356(23):2388-2398 (Pubitemid 46883773)
3. Palmieri L, Bennett K, Giampaoli S, Capewell S (2010) Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 100(4):684-692
4. Wijeysundera HC, Machado M, Farahati F, et al. (2010) Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 303(18):1841-18747
5. Baigent C, Keech A, Kearney PM, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267-1278
6. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670-1681
7. Assmann G, Schulte H, Eckardstein A von, Huang Y (1996) High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124(Suppl):11-20
8. Keys A (1980) Alpha lipoprotein (HDL) cholesterol in the serum and the risk of coronary heart disease and death. Lancet 2(8195 pt 1):603-606 (Pubitemid 10056646)
9. Keys A (1988) High density lipoprotein cholesterol and longevity. J Epidemiol Community Health 42(1):60-65
10. Wolfram G, Schlierf G (1979) LDL-cholesterol and HDL-cholesterol - risk factor and safety factor? Conclusions for therapy. Internist (Berl) 20(12):613-618
11. Nofer JR, Levkau B, Wolinska I, et al. (2001) Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276(37):34480-34485
12. Brewer HB Jr (2011) Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 96(5):1246-1257
13. Schaefer JR, Schweer H, Ikewaki K, et al. (1999) Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144(1):177-184 (Pubitemid 29259979)
14. Saha SA, Arora RR (2011) Hyperlipidaemia and cardiovascular disease: do fibrates have a role? Curr Opin Lipidol 22(4):270-276
15. Ikewaki K, Rader DJ, Sakamoto T, et al. (1993) Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 92(4):1650-1658 (Pubitemid 23304526)
16. Rader DJ, Schaefer JR, Lohse P, et al. (1993) Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism 42(11):1429-1434 (Pubitemid 23335875)
17. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, et al. (2000) Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study. Circulation 102(18):2197-2203
18. Barter PJ, Caulfield M, Eriksson M, et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357(21):2109-2122 (Pubitemid 350146106)
19. Robinson JG (2010) Dalcetrapib: a review of Phase II data. Expert Opin Investig Drugs 19(6):795-805
20. Ridker PM, Genest J, Boekholdt SM, et al. (2010) HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 376(9738):333-339
21. http://www.theheart.org/article/1231453.do
22. Degoma EM, Rader DJ (2011) Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 8(5):266-277